Drug Profile
PL 18
Alternative Names: PL-18; PL-18 polypeptide suppository; PL-18-suppositoryLatest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Jiangsu ProteLight Pharmaceutical and Biotechnology
- Class Anti-inflammatories; Antibacterials; Antifungals
- Mechanism of Action Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bacterial vaginosis; Mycoses; Vaginitis
Most Recent Events
- 07 Sep 2023 Phase-I clinical trials in Vaginitis in China (Vaginal) (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)
- 01 Aug 2022 Phase-I clinical trials in Bacterial vaginosis (In volunteers) in Australia (Vaginal) (NCT05340790)
- 01 Aug 2022 Phase-I clinical trials in Mycoses (In volunteers) in Australia (Vaginal) (NCT05340790)